Background: Glucagon-like peptide 1 agonists differ in chemical structure, duration of action and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. Methods: We randomly assigned patients with type 2 diabetes and cardiovascular disease to the addition of once-weekly subcutaneous injection of albiglutide (30 mg to 50 mg) or matching placebo to standard care. We hypothesized that albiglutide would be noninferior to placebo for the primary outcome of first occurrence of cardiovascular death, myocardial infarction, or stroke. If noninferiority was confirmed by an upper limit of the 95% confidence interval for the hazard ratio of less than 1.30, closed-testing for superiority was prespecified. Findings: Overall, 9463 participants were followed for a median of 1.6 years. The primary composite outcome occurred in 338 of 4731 patients (7.1%; 4.6 events per 100 person-years) in the albiglutide group and in 428 of 4732 patients (9.0%; 5.9 events per 100 person-years) in the placebo group (hazard ratio, 0.78; 95% confidence interval [CI ], 0.68 to 0.90), indicating that albiglutide, was superior to placebo (P<0.0001 for noninferiority, P=0.0006 for superiority). The incidence of acute pancreatitis (albiglutide 10 patients and placebo 7 patients), pancreatic cancer (6 and 5), medullary thyroid carcinoma (0 and 0), and other serious adverse events did not differ significantly between the two groups. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. (Funded by GlaxoSmithKline; Harmony Outcomes ClinicalTrials.gov number, NCT02465515.) noninferiority; P = 0.06 for superiority). There seems to be variation in the results of existing trials with GLP-1 receptor agonists, which if correct, might reflect drug structure or duration of action, patients studied, duration of follow-up or other factors.

No abstract

The study was undertaken to examine the specific features of the lipid spectrum in patients with metabolic disorders in the absence or presence of arterial hypertension (AH) and type 2 diabetes mellitus (DM) The study covered 176 patients with metabolic disorders, 138 patients were diagnosed as having AH, of them 39 patients had type 2 DM Clinical and laboratory studies involved the estimation of the body mass index, waist/hip ratio, and lipid spectrum All the patients were divided into 3 groups I) 38 without AH and type 2 DM, 2) 99 with isolated AH without type 2 DM, 3) 39 with AH and type 2 DM The higher severity of abdominal obesity was associated with enhanced dyslipidemia atherogemcity The development of AH m the presence of metabolic disorders was accompanied by higher total cholesterol levels, which may be considered as aggravated endothelial dysfunction Its concurrence with type 2 DM was attended by transformation of metabolic to diabetic dyslipidemia The study has yielded a new index that characterizes dyslipidemia atherogemcity in patients with metabolic disorders

No abstract